← Back to Search

Shared Decision Making Intervention for Rheumatoid Arthritis (RAiSeD Trial)

N/A
Recruiting
Led By Jennifer Barton, MD
Research Sponsored by VA Office of Research and Development
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion (up to 4 years), on average 3 times per year
Awards & highlights
No Placebo-Only Group

Summary

This trial will test whether a shared decision making intervention can help reduce disease activity, improve medication adherence, and increase patient knowledge about RA in Veterans Affairs (VA) patients with RA.

Who is the study for?
This trial is for adults with moderate to high rheumatoid arthritis activity who have been treated at participating clinics in the past year. It includes patients, clinicians, and non-clinician leaders involved in RA care. Participants must speak English and not have cognitive impairments that would prevent participation.
What is being tested?
The study tests a shared decision-making intervention aimed at improving RA disease outcomes. This involves an RA medication guide (RA Choice), training clinicians on communication, and activating patients to engage in their treatment choices.
What are the potential side effects?
Since this trial focuses on decision-making rather than new medications, it does not directly test treatments with side effects. However, any standard side effects of current RA medications may still apply to participants.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion (up to 4 years), on average 3 times per year
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion (up to 4 years), on average 3 times per year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Disease activity
Secondary study objectives
Change in OPTION-5 (objective measure of shared decision making)
Change in adherence
Change in rheumatoid arthritis knowledge
+2 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: InterventionExperimental Treatment3 Interventions
Intervention phase
Group II: ControlActive Control1 Intervention
Usual care
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Patient activation
2019
N/A
~320

Find a Location

Who is running the clinical trial?

VA Office of Research and DevelopmentLead Sponsor
1,664 Previous Clinical Trials
3,764,805 Total Patients Enrolled
3 Trials studying Rheumatoid Arthritis
222 Patients Enrolled for Rheumatoid Arthritis
Jennifer Barton, MDPrincipal InvestigatorVA Portland Health Care System, Portland, OR

Media Library

RA Medication summary guide and RA Choice Clinical Trial Eligibility Overview. Trial Name: NCT05530694 — N/A
Rheumatoid Arthritis Research Study Groups: Intervention, Control
Rheumatoid Arthritis Clinical Trial 2023: RA Medication summary guide and RA Choice Highlights & Side Effects. Trial Name: NCT05530694 — N/A
RA Medication summary guide and RA Choice 2023 Treatment Timeline for Medical Study. Trial Name: NCT05530694 — N/A
Rheumatoid Arthritis Patient Testimony for trial: Trial Name: NCT05530694 — N/A
~220 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top